These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 19550077

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR.
    Tabb MM, Sun A, Zhou C, Grün F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM, Blumberg B.
    J Biol Chem; 2003 Nov 07; 278(45):43919-27. PubMed ID: 12920130
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
    Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, Sakamaki T, Pestell RG, Yamamoto K.
    Clin Cancer Res; 2007 Apr 01; 13(7):2236-45. PubMed ID: 17404108
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hepatocellular carcinoma and vitamin K.
    Mizuta T, Ozaki I.
    Vitam Horm; 2008 Apr 01; 78():435-42. PubMed ID: 18374204
    [Abstract] [Full Text] [Related]

  • 10. Carboxylic Derivatives of Vitamin K2 Inhibit Hepatocellular Carcinoma Cell Growth through Caspase/Transglutaminase-Related Signaling Pathways.
    Qin XY, Fujii S, Shimizu A, Kagechika H, Kojima S.
    J Nutr Sci Vitaminol (Tokyo); 2015 Apr 01; 61(4):285-90. PubMed ID: 26440634
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
    Ha TY, Hwang S, Hong HN, Choi YI, Yoon SY, Won YJ, Song GW, Kim N, Tak E, Ryoo BY.
    Anticancer Res; 2015 Apr 01; 35(4):1985-95. PubMed ID: 25862851
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells.
    Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, Moriwaki H.
    Cancer Sci; 2007 Mar 01; 98(3):431-7. PubMed ID: 17270033
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Astemizole promotes the anti-tumor effect of vitamin D through inhibiting miR-125a-5p-meidated regulation of VDR in HCC.
    Xu J, Wang Y, Zhang Y, Dang S, He S.
    Biomed Pharmacother; 2018 Nov 01; 107():1682-1691. PubMed ID: 30257386
    [Abstract] [Full Text] [Related]

  • 19. Enhanced antitumor effects of novel intracellular delivery of an active form of menaquinone-4, menahydroquinone-4, into hepatocellular carcinoma.
    Setoguchi S, Watase D, Matsunaga K, Matsubara M, Kubo Y, Kusuda M, Nagata-Akaho N, Enjoji M, Nakashima M, Takeshita M, Karube Y, Takata J.
    Cancer Prev Res (Phila); 2015 Feb 01; 8(2):129-38. PubMed ID: 25416411
    [Abstract] [Full Text] [Related]

  • 20. [Clinical application of vitamin K for hepatocellular carcinoma].
    Mizuta T, Ozaki I.
    Clin Calcium; 2007 Nov 01; 17(11):1693-9. PubMed ID: 17982189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.